12:01 PM EST - Trillium Therapeutics Inc. : announced that it has entered into a collaboration with academic investigators in London, Ontario to explore the therapeutic potential of SIRPaFc, its CD47-blocking agent, in a variety of solid tumour models. Trillium Therapeutics Inc.
shares T.TR are trading unchanged at $0.29.
